Godavari Biorefineries Limited has commenced commercial operations of a new 200 KLPD corn/grain-based distillery at its Sameerwadi Unit on June 29, 2026, pushing its total distillery capacity beyond the existing 600 KLPD base. This strategic expansion introduces a dual-feedstock system, enabling the company to utilize corn and grain alongside sugarcane juice. The move is designed to ensure more resilient production levels, particularly during climate-related disruptions that may impact sugarcane availability, while positioning the company to meet growing demand under India's ethanol blending program.

The project entails an estimated investment of ₹130 Cr, to be financed through a mix of internal accruals and debt. The disclosure was submitted to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Capacity and Investment Details

The following table outlines the key particulars of the capacity addition and the existing operational parameters:

The diversification of feedstock sources is expected to stabilize production volumes and support the company's long-term growth trajectory in the biofuels sector.

Godavari Biorefineries Ltd has been granted a patent by the Japanese Patent Office for its invention, "5-Hydroxy-1,4-naphthalenedione for use in the treatment of cancer." The patent, numbered 7869786, was registered on May 26, 2026, and covers a novel class of compounds that exhibit strong inhibitory effects on cancer and cancer stem cells. This development strengthens the company's intellectual property portfolio in the biotechnology and pharmaceutical domain.

Patent Grant Details

The patent application, numbered 2023-525533, was originally filed on October 26, 2021. The inventors listed on the patent include Sandeep Gawade, Sangeeta Srivastava, Prashant Karkal, and Maithili Atavale. The patent specifically addresses the compound's efficacy against multiple types of cancer, including breast and prostate cancer.

Significance of the Development

Receiving the patent from Japan represents formal recognition of the novelty and inventiveness of Godavari Biorefineries Ltd's cancer treatment compound. Patents in the pharmaceutical and biotechnology sectors serve as critical markers of innovation, providing the company with exclusive intellectual property rights over the compound in the Japanese jurisdiction. The acknowledgment of the compound's strong effects on cancer and stem cells highlights its scientific distinction within the oncology space.